RARE vs DBVT vs BMRN vs ALKS

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate Ultragenyx Pharmaceutical Inc. (RARE) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus BioMarin Pharmaceutical Inc. at 30. 1x.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: ALKS returned -11. 0% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc.

(BMRN) is the lower-risk stock at 0. 65β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 118% more volatile than BMRN relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Ultragenyx Pharmaceutical Inc. grew EPS 7. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, RARE leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -79. 5% for RARE. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioMarin Pharmaceutical Inc.

(BMRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65)). Both have compounded well over 10 years (BMRN: -35. 6%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RARE is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; BMRN is a mid-cap quality compounder stock; ALKS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.